<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3706">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058666</url>
  </required_header>
  <id_info>
    <org_study_id>Aero-02</org_study_id>
    <nct_id>NCT03058666</nct_id>
  </id_info>
  <brief_title>Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients</brief_title>
  <official_title>Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ONY</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AHRM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ONY</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to test the hypothesis that aerosolized Infasurf can decrease the need for intubation
      and instillation of liquid surfactant to the airway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will not be masked. The study objective is to document that aerosolized Infasurf
      is superior to &quot;usual care&quot; and provides for some patients effective surfactant therapy with
      less need for endotracheal intubation and instillation of a surfactant suspension into the
      airway. Two cohorts will be recruited: (a) patients who did not receive surfactant at birth
      who develop RDS in the first hours of life and (b) patients who received instillation of
      surfactant for RDS in the first hour of life, were extubated, and have continuing RDS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of the requirement for endotracheal intubation and instillation of surfactant to &quot;usual care&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary Dysplasia</measure>
    <time_frame>28 days or discharge</time_frame>
    <description>Incidence of Bronchopulmonary Dysplasia defined as oxygen requirement to maintain acceptable blood oxygenation saturations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Acute RDS</measure>
    <time_frame>Randomization to 72 hours of age or to intubation</time_frame>
    <description>Measured by oxygen requirements and respiratory support</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">658</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aerosolized Calfactant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NICU Patients with a clinical diagnosis of RDS
Inspired oxygen ≥25% to maintain adequate oxygen saturation
Not Intubated
Requiring Nasal continuous positive airway pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>There will be no protocol driven interventions in the usual care group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized Calfactant</intervention_name>
    <description>Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.</description>
    <arm_group_label>Aerosolized Calfactant</arm_group_label>
    <other_name>Infasurf</other_name>
    <other_name>Calfactant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solarys</intervention_name>
    <description>Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.</description>
    <arm_group_label>Aerosolized Calfactant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        RDS Patients

          1. NICU patient, ≥1hour of age and &lt;24 hours of age.

          2. Clinical diagnosis of RDS, with or without chest X-ray data.

          3. Inspired oxygen ≥25% to maintain adequate oxygen saturation.

          4. Not intubated

          5. Requiring:

               1. nasal continuous positive airway pressure (nCPAP).

        Exclusion Criteria:

          1. Congenital anomaly limiting care options or requiring early surgery.

          2. Cardiopulmonary decompensation.

               1. hypotension with metabolic acidosis (base excess &lt; -10 meq/l).

               2. Oxygen saturations &lt; 88% at start of aerosolization.

               3. PaCO2 ≥ 60 mmHg at start of aerosolization.

          3. Grade 3 or Grade 4 intraventricular hemorrhage by cranial ultrasound, if known.

          4. Acute hypoxic encephalopathy with or without seizures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Cummings, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corey J Commaroto, RRT</last_name>
    <phone>877.274.4669</phone>
    <phone_ext>124</phone_ext>
    <email>ccommaroto@onyinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel D Swartz, PhD</last_name>
    <phone>877.274.4669</phone>
    <phone_ext>136</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Albert, MD</last_name>
      <phone>716-862-1000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aerosol</keyword>
  <keyword>surfactant</keyword>
  <keyword>calfactant</keyword>
  <keyword>Infasurf</keyword>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>RDS</keyword>
  <keyword>Premature</keyword>
  <keyword>Neonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calfactant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
